




CV Template of KATRD International Conference 2021

| | | | | |
|-------------------------|---|------------------|---------|---|
| Name | Kenneth N Olivier | | |  |
| First Name | Kenneth N | Last Name | Olivier | |
| Country | USA | | | |
| Organization | National Heart, Lung and Blood Institute | | | |
| Current Position | MD, MPH Senior Clinician and Chief, Pulmonary Branch | | | |

Educational Background

Dr Olivier received his undergraduate degree in microbiology from Louisiana State University, his medical degree from Tulane University and Master of Public Health degree in infectious disease epidemiology from the University of North Carolina at Chapel Hill. He completed a residency in internal medicine at the Keesler US Air Force Medical Center and fellowship training in pulmonary and critical care medicine at the University of North Carolina at Chapel Hill.

Professional Experiences

Dr. Olivier's research at the NIH is focused on the pathogenesis and population characteristics of bronchiectasis and chronic airway infection with nontuberculous mycobacteria and he has been actively engaged in therapeutics development in these areas. He directs a longitudinal bronchiectasis cohort which characterizes the phenotype, associated genetic risks and explores treatment optimization for patients with advanced, familial and treatment refractory airway infections. His lab seeks to identify novel therapeutics for NTM lung disease and was instrumental in early clinical studies that led to FDA approval of the first drug for the treatment of refractory *M. avium* complex lung disease.

Professional Organizations

Fellow, American College of Chest Physicians
American Thoracic Society Fellow

Main Scientific Publications

Flume PA, Griffith DE, Chalmers JD, Daley CL, **Olivier K**, O'Donnell A, Aksamit T, Kasperbauer S, Leitman A, Winthrop KL. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. *Chest*. 2021 Feb;159(2):537-543

Bogdanovski K, Chau T, Robinson CJ, MacDonald SD, Peterson AM, Mashek CM, Wallin WA, Rimkus M, Montgomery F, Lucas da Silva J, Gupta S, Ghaffari A, Zelazny AM, **Olivier KN**. Antibacterial activity of high-dose nitric oxide against pulmonary *Mycobacterium abscessus* disease. *Access Microbiol*. 2020;2(9)



Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, **Olivier KN**, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. *Clin Infect Dis*. 2020 Aug 14;71(4):905-913

da Silva JL, Gupta S, **Olivier KN**, Zelazny AM. Antimicrobial peptides against drug resistant Mycobacterium abscessus. *Res Microbiol*. 2020 Jul - Sep;171(5-6):211-214

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, **Olivier KN**, Ordway DJ, Prevots DR, Sacchetti JC, Salfinger M, Sasseti CM, Sizemore CF, Winthrop KL, Zelazny AM. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. *Am J Respir Crit Care Med*. 2019 Apr 15;199(8):947-951

Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ Jr. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. *Am J Respir Crit Care Med*. 2017 Mar 15;195(6):814-823

